Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $40.08, for a total value of $200,400.00. Following the sale, the senior vice president owned 12,965 shares in the company, valued at approximately $519,637.20. This represents a 27.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Amy Bachrodt also recently made the following trade(s):

• On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.58, for a total transaction of $405,800.00.

Maze Therapeutics Trading Up 3.4%

Shares of NASDAQ:MAZE opened at $41.43 on Friday. The company has a 50 day moving average of $36.81 and a 200 day moving average of $24.70. The stock has a market cap of $1.99 billion and a P/E ratio of -1.98. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Analyst Ratings Changes

MAZE has been the topic of a number of research analyst reports. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, September 29th. HC Wainwright upped their price objective on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. Raymond James Financial assumed coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 target price for the company. Finally, Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $43.38.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently bought and sold shares of MAZE. Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after buying an additional 438,274 shares in the last quarter. ARCH Venture Management LLC bought a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $45,362,000. Vanguard Group Inc. boosted its stake in shares of Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after purchasing an additional 915,342 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Maze Therapeutics by 10.0% during the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after purchasing an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after purchasing an additional 758,104 shares during the period.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analysts have been raising ratings and targets (consensus remains a “Buy”, average PT ≈ $43.38), supporting upside expectations. Analyst Ratings/Targets
• Positive Sentiment: Several institutions have increased or initiated stakes (e.g., Vanguard, Frazier, ARCH, Marshall Wace), indicating institutional interest that can underpin the stock. Institutional Ownership Details
• Neutral Sentiment: Recent Q3/Q4 results showed an EPS beat (reported -$0.66 vs. -$0.74 consensus), which is supportive but the company remains unprofitable and clinical-stage. Earnings Summary
• Neutral Sentiment: A de‑minimis sale of 100 shares by insider Atul Dandekar (Dec. 30) is immaterial on its own. Small Form 4
• Negative Sentiment: Atul Dandekar sold 72,400 shares (~$2.94M at ~$40.56) and reduced his stake by ~87.3% — the largest and most sentiment‑negative transaction reported. Dandekar Form 4
• Negative Sentiment: CMO Harold Bernstein sold 45,000 shares (~$1.83M at ~$40.56). Large C‑suite sales can raise questions on insider conviction and add selling pressure. Bernstein Form 4
• Negative Sentiment: SVP Amy Bachrodt sold a total of 15,000 shares across Dec. 29–30 (~$606K combined; sales at ~$40.58 and ~$40.08), materially reducing her stake. Multiple insider sales may weigh on near‑term sentiment. Bachrodt Form 4

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.